Abstract
Studies have demonstrated that miRNA-378 is expressed in various malignant tumors. In the present study, we aimed to explore the expression of serum miRNA-378 and its clinical significance in renal cell carcinoma (RCC) patients. A total of 75 RCC patients, 63 renal cysts (RC) patients and 75 healthy controls were selected. The miRNA-378 level in RCC and RC groups was significantly higher than in healthy control group, with RCC group having the highest level. The miRNA-378 levels were significantly decreased within the same group after surgery. When compared with healthy controls, RC group had higher levels but not significantly (p > 0.05) while levels in RCC group were significantly higher (p < 0.05). miRNA-378 expression was correlated with clinical stage and differentiation degree, but not correlated with patient's age, gender, surgical strategy and tumor diameter. The AUC of miRNA-378 was 0.896, 95% confidence interval was 0.847 to 0.945, and AUC hypothesis testing was statistically significant (p < 0.001, RCC vs healthy control). miRNA-378 shows potential in the diagnosis and prediction of postoperative curative effect of renal cell carcinoma, but further studies with lager samples are needed.
Keywords:
Renal cell carcinoma; microRNA 378; diagnosis; patients; AUC
On request received from the corresponding author, the following article is retracted because the authors noted problems in the statistical analysis of the data, so the conclusions drawn in this study cannot be sustained:
Shi, Lixin, Zhang, Lei, Wang, Chunyang, Sun, Shengkun, Cao, Xiyuan, & Zhang, Xu. (2017). Expression of serum microRNA-378 and its clinical significance in renal cell carcinoma. Genetics and Molecular Biology, 40(2), 525-529.
10.1590/1678-4685-gmb-2016-0121
Prof. Dr. Carlos Frederico Martins Menck
Editor in chief
Publication Dates
-
Publication in this collection
Apr-Jun 2017
History
-
Received
05 May 2016 -
Accepted
24 Nov 2016
